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Abstract 
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir 
(ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic 
nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV 
agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening 
using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase.  
A total of thirty-nine new phosphate prodrugs were synthesised and evaluated against HIV-1 (in in 
vitro and in ex-vivo human tonsillar tissue system) and human herpes viruses. Several ProTide 
compounds showed substantial potency against HIV-1 at low micromolar range while the parent 
nucleosides were not effective. Also, pronounced inhibition of herpesvirus replication was 
observed. A carboxypeptidase-mediated hydrolysis study was performed for a selection of 
compounds to assess the formation of putative metabolites and support the biological activity 
observed.  
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Introduction 
HIV infection currently affects over 36 million people worldwide and caused about 35 million 
deaths.1 The rate of new HIV infections is still increasing, especially in third-world countries.1 
Twenty-six anti-HIV drugs are currently available and they act by interacting with different targets 
essential for the viral replication, such as RT, protease, integrase, or the fusion/entry step.2 The 
current antiretroviral therapy significantly improved the life expectancy of HIV-infected 
individuals by reducing the viral load and postponing the insurgence of AIDS. Despite their 
success these drugs carry some limitations, such as the onset of drug resistance and adverse side-
effects. Whilst the first problem has been addressed using a cocktail of different antiretroviral 
drugs, the second one still dramatically impacts the patients’ compliance.  
Several years ago we discovered that ACV, a gold-standard drug against herpes simplex virus 
(HSV) and varicella zoster virus (VZV) infections, can act as a new potential anti-HIV agent. ACV 
inhibited HIV in the presence of human herpesviruses (HHV) and this activity was attributed to the 
conversion of ACV to its monophosphate form by the HHV-encoded kinases; further 
phosphorylation steps provided the active triphosphate form of ACV able to inhibit HIV-RT.3  
To circumvent the required first phosphorylation step of ACV, that requires HHV kinase activity, a 
series of phosphate prodrugs, so called ProTides, were synthesised. These compounds showed 
anti-HIV activity in the absence of HHV infection, demonstrating their nucleoside kinase 
independence.4, 5 These findings were also supported in a different study, where ACV phosphate 
prodrugs showed a full retention of antiviral activity against HSV-1 and VZV thymidine kinase 
(TK)-deficient strains.6 Unfortunately, these compounds proved to be somewhat cytotoxic in some 
assays.4 To overcome this issue and to better understand the full potential of acyclic nucleoside 
analogues as new anti-HIV agent, we performed a virtual screening on a library of ACV 
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derivatives. We then synthesised and biologically evaluated a series of different acyclic 
nucleosides and their corresponding ProTides and investigated their mechanism of bioactivation 
using a well-established enzymatic method. 
 
Results and Discussion 
Molecular modelling: virtual screening 
The objective of this study was to increase the specificity of the compounds for HIV-1 RT and 
reduce the affinity for the cellular DNA polymerase, while still retaining substrate action for 
adenylate and guanylate kinases. A virtual screening using docking techniques was performed on 
HIV-1 RT, adenylate or guanylate kinase, and a model of DNA polymerase g. The docking using 
nucleoside kinases involved in the first step of drug phosphorylation were not considered since the 
phosphoramidate ProTide approach will be applied to the selected compounds.  
Firstly, a database of 3600 compounds was built considering modifications at the base and at the 
acyclic sugar moieties (Figure 1), including: simple and branched acyclic sugars (brown); oxygen, 
methylene or sulphur at the 2’-position (yellow); substitution at the C-8-position of the base 
including: hydrogen, methyl, fluorine, bromine or chlorine (red); substitution at the C-7-position of 
the base including: nitrogen or carbon (hydrogen or methyl substituted) (blue); substitution at the 
C-6-position of the base including: carbonyl, amine, chlorine, methoxide, ethoxide, phenoxy, 
methylamine, or cyclopropylamine (magenta); substitution at the 2-NH position of the base 
including: hydrogen, methyl, ethyl, phenyl or benzyl (green). 
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Figure 1. Acyclic nucleoside derivatives. 
 
Based on the modification at the 6-position of the nucleobase, the database was divided in two 
groups: 6-carbonyl derivatives (450 compounds), which showed base-pairing with cytidine; and 6-
O-modified and 6-N-modified derivatives (3150 compounds) which showed better base pairing 
with thymidine (Figure 2). 
 
 
Figure 2. Base-pairing of the 6-carbonyl and 6-modified guanine derivatives. 
 
The first screening was performed on HIV-RT using a crystal structure of the enzyme co-
crystallised with tenofovir diphosphate (PDB: 1T05).7 The original structure was used for the 6-
modified ACV derivatives, while the substitution of a thymine by a cytidine was necessary for the 
6-carbonyl derivatives. All the compounds were docked in their triphosphate form and the 
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stereochemistry, where present, was taken into account. For this screening, a root mean square 
deviation (RMSD) < 1 Å between the base of the compounds docked and the base of co-
crystallised tenofovir diphosphate was considered leading to a total of 984 compounds. 
Interestingly, it was observed that branched sugar derivatives were well-tolerated due to the 
presence of a pocket in the proximity of amino acid residues Tyr115 and Phe116, which allowed 
the accommodation of a substitution in the acyclic sugar moiety (Figure 3). Moreover, the 
presence of a cleft that allows a potential substitution at the 2-amino position of the base was 
observed. In addition, substitutions at the 8-position of the base, especially with halogens, were 
well-tolerated. 
Interestingly, the compound that showed the best interactions (RMSD < 0.18 Å) was ganciclovir 
(GCV)-TP (Figure 3), drug of choice for human cytomegalovirus (HCMV) infections. 
 
Figure 3. Docking pose of GCV triphosphate overlapped with tenofovir diphosphate (green) in the 
catalytic site of HIV-RT. 
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For the second screening human adenylate kinase (PDB: 2C95)8 or mouse guanylate kinase (PDB: 
1LVG, 88% human homology)9 were considered for the 6-modified and for the 6-carbonyl 
analogues respectively. For these docking experiments, two different RMSDs were considered: the 
first one regarding the position of the base (<1 Å) and the second one considering the position of 
the phosphate moiety (<3 Å). These two values allowed a good position of the base and a 
reasonable position for the phosphate moiety, which, however, in some cases, was slightly moved 
compared to the crystallized compound. Similar to the results obtained for the HIV-RT docking, 
branched sugar derivatives showed the best docking results in both series. In addition, the halogen 
substitution at the 8-position for the 6-carbonyl series was well-tolerated. This second screening 
led to a total of 218 compounds, with the 6-carbonyl derivatives being preferred over the 6-
modified ones. 
The last part of the virtual screening included the use of human DNA polymerases. It is known that 
the toxicity of nucleoside analogues, especially HIV-1 RT inhibitors, is usually due to interactions 
with these enzymes.10-13 The subtypes of human DNA polymerase mainly involved in the 
cytotoxicity are a and g, with the latter being able to incorporate antiviral nucleotide analogues, 
which then act as a DNA chain terminators and consequently show cytotoxicity.14-17 As the crystal 
structures for both human DNA polymerases have not yet been solved, a model for the human 
polymerase g that covers the polymerase active site with the highest degree of homology with T7 
DNA polymerase18 has been used for the final step of our virtual screening. 
In this case, the results were analysed visually, excluding all the compounds that showed good 
interactions with the catalytic site of the enzyme. A total of twenty-five compounds were 
identified, and amongst these, five compounds were selected which displayed the best scoring for 
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all the three docking experiments and that were easily accessible from a synthetic point of view. A 
summary of the virtual screening is depicted in Figure 4. 
 
Figure 4. Summary of the virtual screening using HIV-RT, adenylate or guanylate kinases, and 
human polymerase g. 
 
Figure 5 shows the five compounds selected from the virtual screening, which are: ganciclovir (1), 
penciclovir (2), 2’-thio derivative of ganciclovir (3), 6-chloropenciclovir (4), and 6-
methoxypenciclovir (5).  
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Figure 5. Selected acyclic nucleoside analogues from the virtual screening. 
 
Chemistry 
The desired phosphoramidates were synthesised using tert-butylmagnesium chloride (tBuMgCl) as 
a coupling reagent, following the procedure reported by Uchiyama,19 which is widely used for the 
synthesis of ProTides. The desired phosphorochloridates were prepared according to our 
established method by coupling the appropriate aryl dichlorophosphate with the appropriate amino 
acid ester to yield the desired compound as an oil.4 
 
Synthesis of ProTides of nucleoside analogue 1. 
For the synthesis of ganciclovir 1 ProTides (Scheme 1), the 2-amino functionality of the guanine 
base was protected using N,N-dimethylamino formamide according to the literature.4 The coupling 
with the appropriate phosphorochloridate (2-8 eq) was performed using an excess of tBuMgCl (2-3 
mol/eq) in a mixture of THF and pyridine. The presence of the extra hydroxyl group in the 
molecule played a crucial role in the synthesis of the desired compounds resulting in some cases 
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only in the isolation of the bisphosphate prodrug (9 and 10). The dimethylformamidine group was 
removed by refluxing in 2-propanol for 24-80 h yielding the desired compounds 15-22.  
 
Scheme 1 
 
 
To overcome the issue related to the bis-phosphorylated side-product, the monomethoxytrityl 
(MMT) of 1 was synthetized using monomethoxytrityl chloride (2.2 eq), triethylamine (3 eq) and 
DMAP (cat.) in DMF. The reaction held two different products: 23 bearing two protecting groups 
at the 2-amino position and at the 3’-hydroxyl position and 24 bearing the monomethoxytrityl 
group only at the 2-amino position.  
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Scheme 2 
 
Compound 23 was then reacted with phenyl(benzoxy-L-alaninyl)-phosphorochloridate (2 eq) in 
the presence of tBuMgCl (2 eq) to yield the desired compound 25; compound 24 was reacted with 
1-naphthyl(benzoxy-L-alaninyl)-phosphorochloridate under the same condition giving the desired 
mono-phosphorylated derivative 26. The deprotection of the monomethoxytrityl group was 
Scheme 2. Reagents and conditions: (i) MMT-Cl, TEA, DMAP, anhydrous DMF, rt, 2 h;  (ii) appropriate 
phosphorochloridate, tBuMgCl, anhydrous THF, rt, overnight; (iii) DCM/MeOH, PTSA, rt, 2 h.
NH
N
N
O
NH2N
OHO
HO
1
i
NH
N
N
O
NHMMTN
OHO 23
NH
N
N
O
NHMMTN
OHO
+
24
ii
ii
NH
N
N
O
NHMMTN
OO
OMMT
OMMT
P
O
O
HN
O
BnO CH3
NH
N
N
O
NHMMTN
OO
OH
P
O
O
HN
O
BnO CH3iii
iii
NH
N
N
O
NH2N
OO
OH
P
O
O
HN
O
BnO CH3
NH
N
N
O
NH2N
OO
OH
P
O
O
HN
O
BnO CH3
25
26
27 28
OH
12 
 
performed using an excess of para-toluene sulfonic acid in DCM/MeOH yielding the desired 
compounds 27 and 28. 
Synthesis of ProTides of nucleoside analogue 2 
The same synthetic approach was applied for the synthesis of compound 2 ProTides. Initially, the 
2-amino functionality of the guanine base was protected under the same conditions seen previously 
to give compound 29 in excellent yield. Unfortunately, the coupling with the appropriate 
phosphorochloridate resulted in the isolation of only the bis-phosphorylated compounds 30 and 31 
for L-alaninyl derivatives; while both bis- (32 and 34) and mono-phosphorylated (33 and 35) 
derivatives were obtained when dimethylglycine phosphorochloridates were used. The protecting 
group was removed by refluxing in 2-propanol to give the final compounds (36-41) in low yield 
due to degradation of the products.  
 
Scheme 3 
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To overcome the issue related to the deprotection step, 2 was directly reacted with 
phenyl(benzoxy-L-alaninyl)-phosphorochloridate yielding compound 42 in very low yield (5%). 
Alternatively, compound 2 was converted to the bis-MMT derivative 43 and subsequently reacted 
with the appropriate phosphorochloridate to give 44. The deprotection step was carried out using 
para-toluene sulfonic acid affording the desired compound 45.  
 
Scheme 4 
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The protection of both 1 and 2 with the para-methoxytrityl group proved to be an effective 
approach for the synthesis of monophosphorylated derivatives, having a milder deprotection step, 
which led to a higher overall yield. 
Synthesis of compound 3 and its ProTides. 
The synthesis of 3 was performed adapting a reported procedure.20 Compound 46, easily made by 
reacting epichlorohydrin with benzyl alcohol in the presence of sodium hydride and tetra-n-butyl 
ammonium iodide, was reacted with tosyl chloride to give derivative 47, which was then converted 
into its thio-acetyl derivative 48 by heating with potassium thioacetate in anhydrous DMF. The 
deprotection of the acetyl group was performed either in methanolic ammonia or using sodium 
methoxide in methanol affording compound 49 in comparable yield. A three-steps coupling 
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reaction between diacetyl-guanine and 48 gave the desired compound 50; the N-7 isomer was also 
isolated during the purification step. The benzyl protecting groups were then converted into acetyl 
groups, using acetic anhydride and BF3.OEt2 to yield 51, which was then fully deprotected using 
methanolic ammonia to obtain the desired compound 3. 
 
Scheme 5 
 
Compound 3 was protected with N,N-dimethylformamide to give 52 in 88% yield followed by the 
coupling with the appropriate phosphorochloridate affording only the bis-phosphorylated 
derivatives 53 and 54. The deprotection was only successful for compound 53 leading the desired 
compound 55; whilst in the case of 54, degradation of the starting material was observed (Scheme 
6). 
 
Scheme 6 
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Synthesis of nucleosides analogues 4 and 5, and their ProTides. 
Compounds 4 and 5 were prepared according to a procedure reported by Toori et al.21 (Scheme 7). 
Compound 2 was acetylated using acetic anhydride and DMAP (cat.) to obtain 57 in good yield. 
Chlorination at the 6-position was achieved using POCl3 in the presence of 
benzyltriethylammonium chloride and N,N-dimethylaniline to yield 58. The deprotection of the 
acetyl group using methanolic ammonia at room temperature led only to the deprotection of the 
acetyl group, giving compound 4; while the use of sodium methoxide in methanol at 40 oC afforded 
compound 5. 
 
Scheme 7 
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Compounds 4 and 5 were coupled with the appropriate phosphorochloridate under the same 
conditions described above. The presence of the 6-chloro or 6-methoxy group greatly improved 
their solubility compared to the previous analogues with the subsequent improvement of their 
reactivity.  
Scheme 8 
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In the case of compound 4, the monophosphorylated derivative 59 and the bisphosphorylated 60 
were obtained in 9% and 24% yield respectively (Scheme 8).  
In the case of compound 5, given the previous success of 6-methoxy purine analogues in another 
antiviral program,22 a wider range of ProTides was considered (Scheme 9). Monophosphorylated 
derivatives (66-72) were obtained most of the time together with the bisphosphorylated ProTides 
(61-65).  
 
 
 
Scheme 9 
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The monophosphorylated ProTides of all the parent nucleosides considered were obtained as an 
inseparable mixture of isomers due to the formation of a new chiral centre at the acyclic sugar 
side-chain. 
 
Scheme 10 
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To overcome this issue, the cyclic ProTides derivatives of 2 and 4 were prepared. Compound 6 
was reacted with ethoxy-L-alaninyl dichlorophosphate using tBuMgCl in THF/pyridine yielding 
compound 73 followed by deprotection in 2-propanol to afford compound 74 (Scheme 10).  
 
Scheme 11 
 
 
Similarly, 4 was directly coupled with benzoxy-L-alaninyl phosphorochloridate providing the 
desired compound 75 (Scheme 11). 
In an attempt to identify the formation of a metabolite in an enzymatic assay which will be 
discussed later, the monoacetylated derivative of 76 and its ProTide 77 were synthesised (Scheme 
12). Treating 58 with ammonia gas generated in situ at 0 oC gave the desired compound 76 in 
moderate yield. The synthesis of ProTide 77 was then performed using a standard procedure 
obtaining the desired compound as a mixture of four diasteroisomers, as clearly depicted in the 
corresponding 31P-NMR spectra.   
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Scheme 12 
 
 
Biological Results 
Anti-HIV activity. The synthesised compounds were first tested for HIV-1 inhibition in MT-4 cell 
cultures (Table 1). While the parent nucleosides 1-5 were inactive against HIV-1, several of the 
ProTides showed anti-HIV activity, with the most potent being in the low µM range. Mono-
ProTides (16, 20, 22, 27, 28) of compound 1 showed anti-HIV activity between 8 and >150 µM 
and an antiproliferative effect between 20 and >150 µM. In the case of bis-ProTides (15, 17, 18, 
19, and 21) the anti-HIV activity varied between 8.5 and >150 µM and the antiproliferative effect 
between 8 and 150 µM. However, for the most active ones (i.e. 15, 17, 19 and 22) the antiviral 
activity can be related to the relatively high cytotoxicity observed for these compounds. 
Penciclovir (2) mono-ProTides (39, 41, 42, and 45) showed an anti-HIV activity in a range 
between 10-95 µM and cytotoxicity at ³100 µM. The phenyl-L-alaninyl-O-benzyl derivative 42 
was the most active in this series, with an EC50= 10 µM and IC50= >150 µM. Its therapeutic 
selectivity index (i.e. ratio IC50/EC50) was > 15. The substitution of the natural amino acid L-alanine 
with the non-natural amino acid dimethylglycine led to a >4-fold reduction of anti-HIV activity. 
As observed in the previous series, the bis-ProTides of 2 (36-38) and the 2-NH2-DMF-protected 
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ProTides 30 and 31 were generally fairly cytotoxic (4-30 µM) and the antiviral activity observed 
may be due to the underlying cytotoxicity.  
Similarly, the bis-ProTides 54 and 55 of nucleoside analogues 3 were cytotoxic (21 and 4 µM, 
respectively) which, as previously observed, may affect the apparent anti-HIV activity. The 2-NH2-
DMF protected ProTides (30, 31 and 54) were tested because the HIV-RT active site showed the 
presence of a cleft in close proximity of the 2-amino position potentially allowing a better 
interaction with this enzyme.  
Compound 60, mono-ProTide of 4,  showed an anti-HIV activity in the low micromolar range (1 
µM) and an IC50 = 20 µM, while bis-ProTide 59 showed a 7-fold loss in antiviral activity while 
retaining cytotoxicity.  
Mono-ProTides (66-72) of nucleoside 5 showed an EC50 in a range between 1.1->150 µM, and an 
IC50 in between 12-92 µM. It must be stated that the majority of the compounds showed a 
substantial antiproliferative effect and the observed anti-HIV activity may result from it, with the 
exception of compound 66, which showed the best inhibitory activity (EC50= 1.1 µM) as well as the 
best selectivity index = 21. This compound has similar biological profile as the best ACV ProTide 
reported in our previous study.4 Interestingly, the substitution of the phenyl moiety with the 
naphthol led to a dramatic loss of activity (>20 fold), which was not observed in the previous 
series. Regarding the bis-ProTides (61-65), these compounds were found to be fairly cytotoxic. 
The cyclic ProTides 74 and 75 were also evaluated in this study, showing an EC50= 22 µM and 
IC50= >150 µM (selectivity index > 7) for compound 74, and EC50= 85 µM and IC50 of 150 µM for 
75. Acetyl protected nucleoside 76 did not show any anti-HIV activity or cytotoxicity (EC50 and IC50 
> 150 µM), ProTide 77 showed an EC50= 2 µM for HIV and an IC50= 10 µM, data similar to its 
related compound 60.  
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Table 1. Anti-HIV activity for synthesized ProTides and their related parent nucleosides in cell 
lines. 
       
Antiviral activity 
EC50a (µM) 
Cytostatic/toxic 
activity (µM) 
Cpds Nucl ProTide Aryl 
Amino 
Acid 
Ester cLogP 
HIV-1 
MT-4 
CC50b 
CEM 
IC50c 
MT-4 
15 1 Bis Naph L-Ala iPr 4.03 8.5 >100 6 
16 1 Mono Naph L-Ala iPr 0.41 40 35±4.2 150 
17 1 Bis Ph L-Ala Bn 3.42 30 159±82 >150 
18 1 Bis Naph L-Ala Bn 5.77 ND ND >150 
19 1 Bis Ph DMG Bn 4.04 10 47 13 
20 1 Mono Ph DMG Bn 0.42 >150 >100 >150 
21 1 Bis Naph DMG Bn 6.39 >150 >20 >150 
22 1 Mono Naph DMG Bn 1.59 10 >100 26 
27 1 Mono Ph L-Ala Bn 0.11 17 ND 20 
28 1 Mono Naph L-Ala Bn 1.28 8 ND 100 
30d 2 Bis Ph L-Ala Bn 4.04 9 21±0 10 
31d 2 Bis Naph L-Ala Bn 6.38 3.2 19±1 4 
36 2 Bis Ph L-Ala Bn 3.83 8 76±2 10 
37 2 Bis Naph L-Ala Bn 6.18 ND >10 ND 
38 2 Bis Ph DMG Bn 4.45 19 100 30 
39 2 Mono Ph DMG Bn 0.87 68 252±32 >150 
40 2 Bis Naph DMG Bn 6.80 >150 >250 >150 
41 2 Mono Naph DMG Bn 2.04 95 96±2 100 
42 2 Mono Ph L-Ala Bn 0.56 10 >250 >150 
45 2 Mono Naph L-Ala Bn 1.73 21 138±6 100 
54d 3 Bis Naph L-Ala Bn 6.14 9 17±2 4 
55 3 Bis Ph L-Ala Bn 3.59 24 77±21 21 
59 4 Bis Ph L-Ala Bn 5.54 7 14±3 20 
60 4 Mono Ph L-Ala Bn 2.27 1 33±8 20 
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61 5 Bis Ph L-Ala Bn 5.79 12 19±7 20 
62 5 Bis Naph L-Ala CH2tBu 8.43 8.2 4.6±0.6 5 
63 5 Bis Naph L-Ala nPr 6.83 9.7 6.8±1.5 20 
64 5 Bis Naph L-Ala 2,2-diMe-But 9.49 5.6 7.2±1.9 9 
65 5 Bis Ph L-Ala Cyclohexyl 6.43 10 7.2±0.5 11 
66 5 Mono Ph L-Ala Bn 2.51 1.1 32±4 23 
67 5 Mono Naph L-Ala Bn 3.69 23 27±2 12 
68 5 Mono Naph L-Ala CH2tBu 3.83 41 17±2 35 
69 5 Mono Naph L-Ala nPr 3.03 11 17±5 13 
70 5 Mono Naph L-Ala Me 1.98 16 15±0 10 
71 5 Mono Naph L-Ala 2,2-diMe-But 4.36 24 18±2 17 
72 5 Mono Ph L-Ala Cyclohexyl 2.83 >150 15±1 92 
74 1 Cyclic - L-Ala Et -0.69 22 ND >150 
75 4 Cyclic  L-Ala Bn 1.55 85 165±90 150 
77 4 monoacetyl Ph L-Ala Bn 3.17 2.25 26±9 10 
76 4 monoacetyl - - - -0.60 >150 ≥250 >150 
1 - - - - - -2.54 >50 >100 >50 
2 - - - - - -2.72 >150 ND >150 
3 - - - - - -2.38 >150 >500 >150 
4 - - - - - -1.01 >150 400±141 >150 
5 - - - - - -0.76 >150 246±0 >150 
a50% Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity by 50%. b50% 
Cytostatic concentration, or compound concentration required to decrease the viability of the cell cultures by 50%.  
c50% Inhibitory concentration, or compound concentration required to inhibit cell proliferation by 50%. ND = not 
determined. dN2-DMF-protected. 
 
Next we tested a selection of ProTides and their respective parent nucleosides using ex-vivo human 
tonsillar tissues infected with HIV and HHV.3 This system of histoculture offers major advantages 
over single cell cultures as it retains tissue cytoarchitecture and many important functional aspects 
of cell–cell interactions in vivo. In particular, cultures of human lymphoid tissue allow the testing 
of anti-HIV drugs upon HIV inoculation ex vivo. Lymphoid tissue explants support productive 
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HIV infection without exogenous cell activation, and retain the pattern of expression of key cell 
surface molecules relevant to HIV infection.23 In this system, 1 proved to be fairly effective in 
inhibiting HIV at an EC50= 5 μM. Compounds 28 and 74, respectively the mono-ProTide and the 
cyclic-ProTide of 1, showed retention of antiviral activity (EC50= 11 and 4.6 µM, respectively) 
demonstrating that the delivery of the monophosphate form of 1 through a ProTide is as efficient 
as the phosphorylation mediated by the HHV-TK present in the tissue cultures. 2 displayed an 
EC50= 11 µM versus HIV-1, result expected since this compound is a well-known anti-HSV drug 
and as such it is an efficient substrate for the HHV-thymidine kinase. This activity was also in 
accordance with the results obtained for its ProTide 42 in the MT4 assay (EC50= 10 µM). An 
important result was obtained for compound 3 which lacked any anti-HIV activity (EC50> 30 µM) 
in this assay, although it functions as a submicromolar anti-HSV compound (as reported in Table 
3). Similar results were obtained for its bis-ProTide 55, which did not inhibit HIV either. We can 
speculate that 3, despite being a very close analogue of 1, is a poor substrate for HIV-RT and the 
inhibitory activity found in the MT-4 cell assay for 54 and 55 was just due to the underlying 
toxicity of these compounds. 
Both compounds 4 and 5 were not effective in this assay (EC50> 60 µM and > 30 µM, respectively), 
while their phosphate prodrugs were able to inhibit HIV in a low micromolar range: EC50= 4 µM 
for mono-ProTide 60 and EC50= 9 µM for cyclic ProTide 74 (both derivatives of nucleoside 
analogue 4); and EC50= 0.9 µM for 66 (mono-ProTide of 5). The lack of activity reported for 4 and 
5 is probably related to their poor conversion to the monophosphate form by TK-HHV. This 
assumption is supported by the lack of anti-HSV activity of these compounds (Table 3). Similar 
result was obtained for the monoacetylated derivative 76 (EC50>10 µM), while its ProTide 77 
showed an EC50= 4 µM. 
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Table 2. Inhibitory Activity of ProTides against HIV-1 in human tonsillar tissues ex vivo.  
       
Cps Nucl ProTide Aryl 
Amino 
Acid 
Ester 
Anti-HIV Activity 
EC50a (µM) 
28 1 Mono Naph L-Ala Bn 11 
42 2 Mono Ph L-Ala Bn >20 
55 3 Bis Ph L-Ala Bn >3 
60 4 Mono Ph L-Ala Bn 4 
66 5 Mono Ph L-Ala Bn 0.9 
74 1 Cyclic - L-Ala Et 4.6 
75 4 Cyclic - L-Ala Bn 9 
77 MonoAcetyl 4 Mono Ph L-Ala Bn 4 
1 - - - - - 5 
2 - - - - - 11 
3 - - - - - >30 
4 - - - - - >60 
5 - - - - - >30 
76 MonoAcetyl 4 - - - - >10 
                     a50% Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity by 50%. 
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Anti-HSV activity. The synthesized compounds were also evaluated for their ability to 
inhibit HSV-1, HSV-2, and a TK-deficient (TK-) HSV-1 strain (ACV-resistant) in 
confluent virus-infected human embryonic lung fibroblasts (HEL cultures) (Table 3). 
Parent compound 1 showed antiviral activity (EC50) of 0.03 µM, 0.04 µM and 4.3 µM 
against HSV-1, HSV-2 and HSV-1 TK-, respectively. Similar to the anti-HIV activity in 
tissues ex vivo, its ProTides were found to be slightly less active compared to the parent 
nucleoside (with an activity against the HSV-1 KOS strain in the range of 0.09-2 µM for 
the mono-ProTides 16, 20, 22, 27 and 28, and in the range of 0.3-3 µM for the bis-
ProTides 15, 17, 19 and 21). Similar activity was obtained against HSV-2 with an EC50 in 
the range of 0.3-3 µM for the mono-ProTides, and 0.9-2.5 µM for the bis-ProTides. As 
expected, while the parent nucleoside 1 showed a loss of activity of ~140-fold against 
HSV-1 TK-, some of the ProTides (mono- and bis-) showed a good retention of the 
antiviral activity against this strain. In particular, compounds 18, 19, 20 and 22 showed a 
full retention of antiviral activity (<2.5 fold difference in EC50 values between the HSV-1 
TK+ and TK- strains). While compounds 17, 21 and 28 still show considerable activity 
against these two HSV-1 strains, compounds 15 and 16 displayed marginal activity 
against the TK- mutant virus. No cytotoxicity was observed for any of these compounds 
(MCC> 100 µM). 
In spite of being at least 15-fold (for HSV-1) and 30-fold (for HSV-2) less potent than the 
parent nucleoside, the majority of these compounds were found as active as ACV, the 
current drug of choice for HSV infections. 
Mono-ProTides 39, 41, 42, and 45 showed a loss of antiherpes activity of ~16- to 150-
fold against wild-type HSV-1, and ~27- to 132-fold against HSV-2 compared to the 
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parent nucleoside 2 (EC50= 0.5, 0.6 and 4 µM against HSV-1, HSV-2 and HSV-1 TK- 
strain, respectively). In addition, no activity was found for the mono-ProTides of 2 
against the HSV-1 TK- strain. Contrary to the results observed for derivatives of 1, bis-
ProTides of 2 (compounds 30, 31, 37, 38, and 40) were found to be inactive against the 
three HSV strains. Similarly, compounds 54 and 55 (i.e. bis-ProTides of 3) were found 
inactive (EC50= >100 µM) against HSV-1 and HSV-2, while the parent compound 3 
showed a sub-micromolar activity. 
Compound 5 did not show any anti-HSV activity (EC50>100 µM). Its mono-ProTide 
derivatives, with the exception of compound 70, which showed a good to moderate 
inhibitory activity (EC50= 9-38 µM and EC50= 9-20 µM against HSV-1 and HSV-2, 
respectively), with retention of some activity against the TK- strain for compounds 66, 67, 
68, and 72. Compound 68, bearing the naphthyl as an aryl group, L-alanine as an amino 
acid and neopentyl as an ester, showed the best antiviral profile with an EC50 of 9 µM, 9 
µM and 15 µM against HSV-1, HSV-2 and HSV-1 TK-, respectively. In this series, as 
already observed for derivatives of 2 and 3, the bis-ProTides 61, 62, 63, 64, and 65 were 
found totally inactive (EC50>100 µM). 
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Table 3. Anti-HSV activity of the synthesized ProTides and their corresponding parent 
nucleosides. 
      
Antiviral Activity 
EC50 (µM)a 
Cytotoxicity 
(µM) 
Cps Nucl ProTide Aryl 
Amino 
Acid 
Ester 
HSV-1 
(KOS) 
HSV-2 
(G) 
HSV-1 TK- 
(KOS) 
MCCb 
15 1 Bis Naph L-Ala iPr 1.2 ± 1.1 1.4 ± 0.8 ≥73 ± 39 ≥100 
16 1 Mono Naph L-Ala iPr 2 ± 0 3.0 ± 1.4 ≥75 ± 35 >100 
17 1 Bis Ph L-Ala Bn 3.0 ± 1.4 2.5 ± 2.1 14.5 ± 7.8 >100 
18 1 Bis Naph L-Ala Bn 1.3 ± 1.1 2.5 ± 2.1 2.5 ± 2.1 >100 
19 1 Bis Ph DMG Bn 1.5 ± 0.8 2.5 ± 2.1 1.5 ± 0.7 ND 
20 1 Mono Ph DMG Bn 0.09 ± 0.02 
0.30 ± 
0.28 
0.15 ± 0.07 >100 
21 1 Bis Naph DMG Bn 0.30 ± 0.28 
0.90 ± 
0.14 
1.6 ± 0.6 >100 
22 1 Mono Naph DMG Bn 0.60 ± 0.28 
0.85 ± 
0.07 
1.4 ± 0.8 >100 
27 1 Mono Ph L-Ala Bn 0.6 ± 0.4 3.0 ± 1.4 3.0 ± 1.4 >100 
28 1 Mono Naph L-Ala Bn 0.4 ± 0 0.5 ± 0.1 3.0 ±1.4 >100 
30c 2 Bis Ph L-Ala Bn >100 >100 >100 >100 
31c 2 Bis Naph L-Ala Bn >100 >100 >100 >100 
36 2 Bis Ph L-Ala Bn >100 >100 >100 >100 
37 2 Bis Naph L-Ala Bn >100 >100 >100 >100 
38 2 Bis Ph DMG Bn >100 >100 >100 >100 
39 2 Mono Ph DMG Bn 29 ± 13 39 ± 27 100 ± 0 >100 
40 2 Bis Naph DMG Bn >20 >20 >20 100 
41 2 Mono Naph DMG Bn 75 ± 35 52 ± 9 >100 ± 0 >100 
42 2 Mono Ph L-Ala Bn 8.0 ± 6.0 16 ± 6.0 ≥100 >100 
45 2 Mono Naph L-Ala Bn 73 ± 39 79 ± 30 >100 ± 0 >100 
54c 3 Bis Naph L-Ala Bn >100 >100 >100 ≥100 
55 3 Bis Ph L-Ala Bn >100 >100 >100 ≥100 
59 4 Bis Ph L-Ala Bn >100 >100 >100 >100 
60 4 Mono Ph L-Ala >100 >100 >100 >100 >100 
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61 5 Bis Ph L-Ala Bn 100 >100 100 >100 
62 5 Bis Naph L-Ala CH2tBu >100 >100 >100 ≥100 
63 5 Bis Naph L-Ala nPr >100 >100 >100 ≥100 
64 5 Bis Naph L-Ala 2,2-diMe-But >100 >100 >100 ≥100 
65 5 Bis Ph L-Ala Cyclohexyl >100 >100 >100 >100 
66 5 Mono Ph L-Ala Bn 39 ± 27 29 ± 23 39 ± 27 >100 
67 5 Mono Naph L-Ala Bn 38 20 20 >100 
68 5 Mono Naph L-Ala CH2tBu 9.0 ± 1.4 9.0 ± 0 15 ± 7 >100 
69 5 Mono Naph L-Ala nPr 14 ± 2 15 ± 8 ≥20 100 
70 5 Mono Naph L-Ala Me >100 >100 >100 ≥100 
71 5 Mono Naph L-Ala 2,2-diMe-But 11 ± 2 10 ± 1 ≥20 100 
72 5 Mono Ph L-Ala Cyclohexyl 16 ± 6 16 ± 6 40 ± 28 ≥100 
74 1 Cyclic - L-Ala Et ND ND ND ND 
75 4 Cyclic - L-Ala Bn >100 >100 >100 >100 
ACV - - - - - 0.4 ± 0.5 0.4 ± 0.3 60 ± 82 >250 
1 - - - - - 0.03 ± 0.03 
0.04 ± 
0.03 
4.3 ± 6.4 >100 
2 - - - - - 0.5 ± 0.2 0.6 ± 0.3 4.0 >100 
3 - - - - - 0.4  ± 0.1 0.5 ± 0.1 1.6 ± 1.1 >100 
4 - - - - - >100 >100 >100 >100 
5 - - - - - >100 >100 >100 >100 
a50% Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity 
by 50%. bMinimum cytotoxic concentration, or compound concentration required to cause a 
microscopically detectable alteration of normal cell morphology. cN2-DMF-protected.  ND = not 
determined. 
 
Anti-HCMV activity. The synthesized compounds were also evaluated for their ability 
to inhibit two strains (AD-169 and Davis) of HCMV in confluent HEL cell cultures 
(Table 4). Compound 1 showed an EC50 of 7.4 µM (AD-169 strain) and 7.3 µM (Davis 
strain); its mono-ProTides showed an EC50 in a range between 6.6->50 µM (AD-169 
strain) and in a range between 4.9-24 µM (Davis strain); the bis-ProTides showed a loss 
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of activity compared to the mono-ProTides. Compounds 22, 27 and 28 were the most 
active of this series with EC50’s comparable to that of the parent nucleoside. Compounds 2 
and 3 and their ProTides showed poor, if any activity against HCMV (EC50≥ 50 µM). The 
6-methoxy-PCV 5 did not show any activity against HCMV (EC50> 50 µM), while some 
mono- and bis-ProTides showed a moderate anti-HCMV activity, which, however, could 
be related to the cytotoxicity of these compounds (CC50 ‘s in the range of 1.6 to ≥83 µM). 
 
Anti-VZV activity. A biological evaluation against two strains (OKA and 07-1 TK-) of 
VZV was also performed in monolayer HEL cell cultures (Table 4). Compounds 20 and 
27 emerged as the most potent mono-ProTides of 1 with a high antiviral activity against 
VZV in the low µM range for both strains (EC50= 7.3 µM against the TK+ VZV strain 
Oka) and excellent retention of activity against the TK- VZV strain 07-1 (EC50= 3.2-3.3 
µM). These compounds were slightly less active than the current drug treatment of choice 
(ACV) against the TK+-OKA strain. However, they showed to be at least ~20 fold more 
active against the ACV-resistant VZV TK- 07-1 strain. 
Both mono- and bis-ProTides of 2 showed at least a 10-fold loss of anti-VZV activity 
compared to the parent compound and proved also poorly effective against the TK-
deficient VZV strain. Similarly, poor activity was also found for ProTides 54 and 55. 
None of the mono- and bis-ProTides of 4 and 5 displayed significant anti-VZV activity at 
non-toxic concentrations.
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Table 4. Anti-HCMV and –VZV activity of the synthesized ProTides and their corresponding 
parent nucleosides 
      
Antiviral Activity 
EC50 (µM)a 
Cytotoxicity 
(µM) 
Cpds Nucl ProTide Aryl 
Amino 
Acid 
Ester 
HCMV 
(AD-169) 
HCMV 
(Davis) 
TK+ VZV 
(OKA) 
TK- VZV 
(07-1) 
CC50b 
MCCc 
 
15 1 Bis Naph L-Ala iPr 16.3 ± 5.2 2.7 ± 1.5 4.2 ± 1.9 1.1 ± 0.4 >50 >100 
16 1 Mono Naph L-Ala iPr >50 ± 0 6.8 ± 4.6 ≥23.5 ± 4.9 ≥10.8 ± 13 >50 >100 
17 1 Bis Ph L-Ala Bn 44.7 N.D. 23.3 21.3 >100 >100 
18 1 Bis Naph L-Ala Bn 27.4 ± 10.4 11.2 ± 0.3 6.2 ± 1.0 4.1 ± 0.7 >100 >50 
19 1 Bis Ph DMG Bn 50 ± 0 23.6 ± 11.4 21.7 ± 7.7 8.3 ± 3.2 82 ± 6 >50 
20 1 Mono Ph DMG Bn 38.6 ± 16.2 15.8 ± 6.0 7.3 ± 0.7 3.3 ± 1.4 >100 >50 
21 1 Bis Naph DMG Bn ≥44.9 ± 7.2 50 13.6 ± 4.5 7.2 ± 2.1 >100 >50 
22 1 Mono Naph DMG Bn 6.6 ± 4.8 4.9 ± 3.1 13.0 ± 5.3 >50 >100 >50 
27 1 Mono Ph L-Ala Bn 7.9 ± 1.5 5.0 ± 1.4 7.3 ± 4.3 3.2 ± 1.4 ≥81 ± 27 >100 
28 1 Mono Naph L-Ala Bn 9.5 ± 3.1 6.5 ± 3.5 9.5 28.2 N.D. >100 
30d 2 Bis Ph L-Ala Bn >50 >50 29.8 ± 3.5 28.6 ± 1.1 47 ± 3 >50 
31d 2 Bis Naph L-Ala Bn >20 >20 8.8 ± 2.9 11.7 ± 4.3 19 ± 1 50 
36 2 Bis Ph L-Ala Bn >50 >50 16.3 ± 10.5 41.5 ± 12.0 ≥100 >50 
37 2 Bis Naph L-Ala Bn >50 >50 13.5 ± 5.1 >50 ± 0 >100 >50 
38 2 Bis Ph DMG Bn >50 >50 10.3 ± 2.5 20.6 ± 9.5 >100 >50 
39 2 Mono Ph DMG Bn >50 >50 >50 >50 >50 >50 
40 2 Bis Naph DMG Bn >50 >50 >50 >50 >100 >50 
41 2 Mono Naph DMG Bn >50 >50 20.9 ± 3.5 >50 ± 0 >100 >50 
42 2 Mono Ph L-Ala Bn >50 >50 2.6 ± 0.4 45.0 ± 7.1 >100 >50 
45 2 Mono Naph L-Ala Bn >50 >50 9.3 ± 1.0 >50 >100 >50 
54d 3 Bis Naph L-Ala Bn >50 >50 >20 >20 30 >50 
55 3 Bis Ph L-Ala Bn >50 >50 23 >50 >100 >50 
59 4 Bis Ph L-Ala Bn >100 >100 44.0 ± 4.3 44.1 ± 2.7 4.0 ± 0 >100 
60 4 Mono Ph L-Ala Bn >100 >100 37.3 ± 8.8 42.9 ± 0.9 39 ± 2 >100 
61 5 Bis Ph L-Ala Bn >50 37 22 20 25 >50 
62 5 Bis Naph L-Ala CH2tBu 15 20 4.3 7.7 2.5 ³20 
63 5 Bis Naph L-Ala nPr 32 40 6.1 8.1 4.9 ³50 
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64 5 Bis Naph L-Ala 
2,2-diMe-
But 
>20 >20 6.4 9.5 5.0 50 
65 5 Bis Ph L-Ala Cyclohexyl >20 >20 >5 >5 1.6 50 
66 5 Mono Ph L-Ala Bn 31.6 ± 0 7.9 ± 1.1 17.1 ± 11.0 22.2 ± 5.7 ≥83 ± 25 >50 
67 5 Mono Naph L-Ala Bn >50 50 17 23 49 >50 
68 5 Mono Naph L-Ala CH2tBu 50 40 2.0 6.2 7.6 >50 
69 5 Mono Naph L-Ala nPr 32 50 3.7 9.1 14.4 ³50 
70 5 Mono Naph L-Ala Me 32 14 13 25 37 ³50 
71 5 Mono Naph L-Ala 
2,2-diMe-
But 
43 >50 4.4 9.7 28 ³50 
72 5 Mono Ph L-Ala Cyclohexyl 32 20 5.0 9.4 7.4 >50 
74 1 Cyclic - L-Ala Et N.D N.D N.D N.D N.D N.D 
75 4 Cyclic - L-Ala Bn N.D N.D N.D N.D N.D N.D 
ACV - - - - - ND ND 1.88 ± 0.99 73.0 ± 36.5 787 ± 367 >400 
1 - - - - - 7.4 ±2.1 7.3 ± 3.8 N.D. N.D. 273 ± 121 ≥350 
2 - - - - - >50 >50 0.62 ± 0.53 10.2 ± 2.8 >100 >100 
3 - - - - - >50 40.8 ± 13.0 6.9 ± 2.2 >50 >100 >50 
4 - - - - - >50 >50 >50 >50 >100 >50 
5 - - - - - >50 >50 22.8 ± 0 >50 >100 >50 
a50% Effective concentration, or compound concentration required to inhibit virus-induced cytopathicity by 50%. 
b50% Cytostatic concentration, or compound concentration required to decrease the viability of the cell cultures by 
50%. cMinimum cytotoxic concentration, or compound concentration required to cause a microscopically detectable 
alteration of normal cell morphology. dN2-DMF-protected. ND = not determined.
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Enzymatic Studies: mechanism of bioactivation of ProTides 
It has earlier been observed that ProTides often enhance both solubility and 
permeability.22 Therefore, the loss of biological activity of several of the compounds, 
might be related to other issues, including bioactivation. The putative mechanism of 
bioactivation of the phosphoramidate ProTide moiety involves two subsequent enzymatic 
steps (Scheme 13). The ester moiety of a general ProTide depicted as 78 (red) is cleaved 
by an esterase- or carboxypeptidase-type enzyme to give compound 79 (blue). The 
negatively charged oxygen attacks the phosphorous with the release of the aryl moiety 
forming the unstable mixed anhydride 80 (magenta), which is consequently opened by 
the water yielding compound 81 (green). The phosphorous-nitrogen bond of 81 is then 
cleaved by a phosphoramidase-type enzyme to release the monophosphate form 82 
(yellow).  
 
 Scheme 13. Putative mechanism of bioactivation of ProTides. 
 
The first bioactivation step for a selection of mono- and bis- ProTides as well as cyclic 
derivative 75 was investigated. This experiment involved the incubation of the 
appropriate compound with carboxypeptidase Y using 31P-NMR to follow the metabolism 
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of the starting material. For all the experiments a 31P-NMR of the starting material was 
registered prior to the addition of the enzyme, and then 31P-NMR spectra were registered 
every 5-10 min for a minimum period of 14 h. This experiment allowed understanding 
whether any lack of antiviral activity was due to a poor activation of the ProTide moiety 
with the subsequent low conversion to the monophosphate form. 
 
Figure 6. Carboxypeptidase-mediated cleavage of compound 16, monitored by 31P-
NMR. 
 
Compound 16 (Figure 6, red) showed a slow and incomplete conversion to the metabolite 
81 (dP = 7 ppm, green), which appeared within 1 h of incubation with the enzyme. After 
24 h, the starting compound 16 was still well-detected. Therefore, a partial conversion of 
the starting material into the first metabolite could be noticed. 
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Figure 7. Carboxypeptidase-mediated cleavage of compound 45, monitored by 31P-NMR. 
 
Also for compound 45 (Figure 7), a slow and incomplete conversion of the starting 
material (red) to the metabolite 81 (dP = 7.5 ppm, green) was observed. The formation of 
the intermediate metabolite 79 (dP = 4.16, 4.08, 4.00 ppm, blue) was observed and its 
disappearance indicated its conversion to the desired metabolite 81. Interestingly, the 
formation of an unknown species (dP = 5.67, 5.59 ppm, orange) was observed after 15 
min and constantly increased with time.  
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Figure 8. Carboxypeptidase-mediated cleavage of compound 63, monitored by 31P-NMR. 
 
Compound 63 (Figure 8, red), as an example of a bis-ProTide, showed a fast conversion 
to the first metabolite 79 (blue), which was then partially converted to the second 
metabolite 81 (green). Notably, the presence of two peaks (dP = 7.00, 7.20 ppm) reflect 
the presence of two phosphorus groups. 
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Figure 9. Carboxypeptidase-mediated cleavage of compound 69, monitored by 31P-NMR. 
 
As depicted in Figure 9, the mono-ProTide 69 showed a complete conversion of the 
starting material (red) within 2 h from the start of the experiment to the desired 
metabolite (green). The intermediate 79 (blue) was barely detectable indicating a fast 
conversion to metabolite 81. As already observed for other mono-ProTides, an unknown 
species at dP = ~5.5 ppm (orange) did also appear in this experiment. 
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Figure 10. Carboxypeptidase-mediated cleavage of compound 60, monitored by 31P-
NMR. 
 
Compound 60 (Figure 10, red) was completely converted within 30 min upon the 
addition of the enzyme to the desired metabolite (dP = ~7.0 ppm, green), through the 
intermediate 79 (blue). Also in this case, the species at dP = 5.5, 5.6 ppm (orange) was 
formed and increased in the first 30 minutes of the experiment and then appeared to 
remain constant for the whole duration of the experiment. In this experiment, it is easy to 
note two distinct peaks, which is usually related to the presence of a chiral phosphorous. 
In addition, this compound did not seem to be a substrate for the carboxypeptidase since 
the addition of two extra portions of enzyme did not have any effect on this compound. 
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The enzymatic studies performed showed a partial (compounds 16, 45, and 63) to full 
(compounds 60 and 69) conversion of the starting material to the desired metabolite 81 
and the unknown species at 5-5.5 ppm. We hypothesise that this unknown species 
corresponds to the product of intramolecular cyclisation with the 3’-OH attacking the 
phosphorus center, and being in competition with the carboxylate released by the 
enzymatic cleavage. 
To investigate and confirm this pathway, an enzymatic experiment was designed and 
performed using the cyclic derivative 75 (Scheme 14), and its conversion was monitored 
by 31P-NMR (Figure 11) as well as by mass spectroscopic analysis. 
  
Scheme 14. Putative mechanism of bioactivation for compound 75. 
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Figure 11. Carboxypeptidase-mediated cleavage of compound 75, monitored by 31P-
NMR. 
 
Within 1 h, compound 75 (Figure 11, red) was completely metabolised to the first 
intermediate lacking the ester moiety (dP = 5.3, 5.4 ppm, orange) and having a similar 
chemical shift as the unknown species observed in the previous experiments. The identity 
of this compound was supported by mass spectroscopic analysis (M+H+: 404). The 
conversion to the final metabolite 84 (dP = ~7.0 ppm, green) was observed after 2.5 h and 
it appeared to be the only species after 8 h. Mass spectroscopic analysis confirmed the 
formation of the metabolite 84 (M+2Na+: 467). From these results, we can now 
confidently postulate that the formation of the peak at 5-5.5 ppm observed for the 
compounds analysed can be attributed to the formation of the corresponding cyclic 
intermediate, due to an intramolecular competition between the 3’-OH versus the 
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carboxylate, which did not lead to the formation of the desired compound indicated as 81 
in Figure 6. Interestingly, intermediate 83 can still undergo attack from the carboxylate to 
the phosphorus followed by water-mediated opening of the mixed anhydride resulting in 
the formation of metabolite 84.  
 
Figure 12. Carboxypeptidase-mediated cleavage of compound 77, monitored by 31P-
NMR. 
 
To further support this hypothesis, the monoacetylated ProTide 77 was also studied 
(Figure 12).  The compound proved to be an efficient substrate for the carboxypeptidase 
and it was quickly metabolised to the intermediate (dP = 4.35, 4.28, 4.16 ppm, blue) 
followed by spontaneous conversion to the desired metabolite (dP = ~7.0 ppm, green). As 
anticipated, the formation of an unknown species at 5-5.5 ppm was not observed 
supporting our hypothesis of the need of a free 3’-OH to form this metabolite.  
It is worth to note the fast conversion of only one diastereoisomer, whilst the metabolism 
of the other three proceeded more slowly, although a full conversion was observed within 
12 h. The difference in the rate of conversion for the different diastereoisomers had 
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already been observed previously. 4 Docking studies using the carboxypeptidase Y 
enzyme showed indeed the ability of the enzyme to discriminate between 
diasteroisomers.4  
 
Conclusion 
Previously we showed that the anti-herpetic drug ACV, an acyclic nucleoside analogue, 
has direct anti-HIV suppressive activity ex vivo2 and in vivo.24 The anti-HIV activity of 
ACV is dependent on its prior phophorylation by HHV-TK. To bypass this requirement, 
we developed a series of ACV ProTides that showed pronounced anti-HIV activity, low 
toxicity but somewhat cytostatic activity.4 Here, to overcome this problem and to assess 
the potential of acyclic nucleoside analogues as anti-HIV drugs, we performed a virtual 
screening of a library of acyclic nucleoside derivatives. Docking experiments with a 
database of 3,600 compounds against three different enzymes (HIV RT, adenylate or 
guanylate kinase and a model of DNA polymerase g) resulted in selecting 5 compounds 
that potentially were the strongest RT inhibitors and the weakest cellular DNA 
polymerase inhibitors. The five compounds selected were: ganciclovir (1), penciclovir 
(2), the 2’-thio derivative of ganciclovir (3), 6-chloropenciclovir (4), and 6-
methoxypenciclovir (5). Altogether, 39 phosphate prodrugs were synthesised and 
assessed for their potency against HIV and three HHVs, namely HSV, VZV and HCMV. 
Most of the compounds were inhibitory against HIV with activity in the low µM range, 
but some toxicity was observed, except for compound 66. Some of the mono- and bis-
ProTides of 1 were active against HSV, VZV and HCMV, and were found to be 
equipotent to ACV, but not superior to their parent nucleoside ganciclovir 1. 
Interestingly, they were also active against their TK-deficient counterparts, which is an 
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advantage over ACV. Mono- and bis-ProTide derivatives of compounds 2, 3 and 5 did 
not display important acitivty against HHVs tested in this study. 
Finally, we investigated the mechanism of bioactivation for these compounds using a 
well-established enzymatic assay. The majority of the compounds were found to be 
substrate for the first enzyme involved in the activation pathway to release the 
intermediate indicated in Scheme 13 as compound 81. However, in some cases formation 
of a stable 3’-5’-cyclic-phosphate was also observed; the formation of this compound was 
supported by experiments depicted in Figure 11 and 12.   
   
Experimental Section 
All anhydrous solvents were purchased from Sigma–Aldrich and amino acid esters from 
Novabiochem. All commercially available reagents were used without further 
purification. Thin Layer Chromatography (TLC): precoated aluminium-backed plates (60 
F254, 0.2 mm thickness, Merck) were visualized under both short- and long-wave UV 
light (254 and 366 nm). Flash column chromatography was carried-out using silica gel 
supplied by Fisher (60A, 35–70 μm). Analytical and semipreparative High Performance 
Liquid Chromatography (HPLC) analysis was performed using either a ThermoScientific 
or a Varian Prostar 335 LC detector system using Varian Polaris C18-A (10 µM) as an 
analytical column and Varian Polaris C18-A (10 µM) as a semipreparative column. 1H-
NMR (500 MHz), 13C-NMR (125 MHz), 31P-NMR (202 MHz) spectra were recorded on a 
Bruker Avance 500 MHz spectrometer at 25 °C. Chemical shifts (δ) are quoted in parts 
per million (ppm) relative to internal MeOD (δ 3.34 1H NMR, δ 49.86 13C NMR) and 
CDCl3 (δ 7.26 1H NMR, δ 77.36 13C NMR) or external 85% H3PO4 (δ 0.00 31P 
NMR). Coupling constants (J) are given in Hertz. The following abbreviations are used in 
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the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), qn 
(quintet), m (multiplet), bs (broad singlet), dd (doublet of doublet), dt (doublet of triplet). 
Low-resolution and high-resolution mass spectrometry was performed on a Bruker 
Daltonics microTof-LC system, as a service by the School of Chemistry at Cardiff 
University.Compound purity was assured by a combination of high field multinuclear 
NMR (H, C, P), elemental analysis and/or HPLC. Purity by the later was always always 
>95% with no detectable parent nucleoside for all final products. 
 
Chemistry 
Standard Procedure A: Synthesis of Phosphoramidates  
To a stirring suspension of appropriate nucleoside (1.00 mol/equiv) in anhydrous THF, a 
1.0M solution of tBuMgCl (2.00 mol/equiv) in THF was added dropwise under an argon 
atmosphere and the reaction mixture was stirred at room temperature for 30 min. Then 
the appropriate phosphorochloridate (1.50 to 8.00 mol/equiv) was added dropwise a 
solution of in anhydrous THF. The reaction mixture was stirred at room temperature for 
24-84 h. The solvent was removed under reduced pressure, and the residue was purified 
by column chromatography. 
 
Synthesis of 
N'-(9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,
N-dimethylmethanimidamide (6). To a suspension of 1 (0.50 g, 1.96 mmol) in 
anhydrous DMF (10 mL) was added N,N-dimethylformamide dimethyl acetal (1.30 mL, 
9.79 mmol) and the reaction mixture was stirred at room temperature for 22 h. After this 
period was added N,N-dimethylformamide dimethyl acetal (0.65 mL, 4.90 mmol) and the 
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suspension was stirred at room temperature for 7 h. The suspension was then filtered, and 
the solid was washed with diethyl ether to give a colourless solid (84%, 0.51 g). 1H-NMR 
(DMSO 500 MHz): d 11.31 (1H, s, NH), 8.57 (1H, s, 1H), 7.93 (1H, s, H-8), 5.54 (2H, s, 
H-1’), 4.64 (2H, bs, 2xOH), 3.66-3.60 (1H, m, H-3’), 3.49-3.43 (4H, m, H-4’, H-5’), 
3.16, 3.04 (6H, 2s, N(CH3)2). 
 
Synthesis of (N'-(9-[(1,3-dihydroxypropan-2-yloxy)me-thyl]-6-oxo-6,9-dihydro-1H-
purin-2-yl)-N,N-dimethylformimidamide)-[1-naphthyl(isopropoxy-L-alaninyl)] 
diphosphate (7) and 
N'-(9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-N,
N-dimethylmethanimidamide-[1-naphthyl(isopropoxy-L-alaninyl)] phosphate (8). 
Prepared according to Standard Procedure A, from 6 (0.25 g, 0.81 mmol) in anhydrous 
THF (15 mL), tBuMgCl (1.0 M THF solution, 1.61 mL, 1.61 mmol), 1-naphthyl-(iso-
propoxy-L-alaninyl)-phosphorochloridate (0.86 g, 2.42 mmol) in anhydrous THF (10 
mL) and the reaction mixture was stirred at room temperature overnight. After this period 
pyridine (5 mL), tBuMgCl (1.0 M THF solution, 1.61 mL, 1.61 mmol) and 1-naphthyl-
(iso-propoxy-L-alaninyl)-phosphorochloridate (1.60 g, 4.49 mmol) in anhydrous THF (10 
mL) were added and the reaction mixture was stirred at room temperature for 3 days. The 
residue was purified by column chromatography gradient elution of DCM/MeOH = 98/2, 
then 95/5, to give 7 as a colourless solid (44%, 0.34 g), 31P-NMR (MeOD, 202 MHz): d 
4.04 (bs). Compound 8 was obtained as a colourless solid (14%, 0.071 g) 31P-NMR 
(MeOD, 202 MHz): d 4.19 (bs). 1H-NMR (MeOD, 500 MHz): d 8.74-8.68 (1H, m, 
NCHN(CH3)2), 8.17-7.36 (8H, m, H-8, Naph), 5.73-5.70 (2H, m, H-1’), 4.99-4.80 (1H, bs, 
COOCH(CH3)2), 4.39-4.05 (3H, m,  H-3’, H-5’), 3.97-3.88 (1H, m, CHCH3), 3.70-3.56 
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(2H, m, H-4’), 3.20, 3.12 (6H, s, N(CH3)2), 1.33-1.28 (3H, m, CHCH3), 1.22-1.16 (6H, m, 
COOCH(CH3)2). 
 
Synthesis of 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}- 
6,9-dihydro-1H-purin-6-one-[1-naphthyl(isopropoxy-L-alaninyl)] diphosphate (15). 
A solution of 7 (0.33 g, 0.35 mmol) in 2-propanol (10 mL) was stirred under reflux for 80 
h. After this period the solvent was removed and the residue purified by column 
chromatography gradient elution of DCM/MeOH = 95/5, then 94/6, then 93/7, to give 15 
as a colourless solid (8%, 0.025 g). 31P-NMR (MeOD, 202 MHz): d 4.29, 4.25, 4.23, 4.17. 
1H-NMR (MeOD, 500 MHz): d 8.17-8.05 (2H, m, H-8 Naph), 7.85 (2H, m, H-6 Naph), 
7.75-7.71 (1H, m, H-8), 7.68-7.34 (10H, m, Naph), 5.41-5.37 (2H, m, H-1’), 4.99-4.87 
(2H, m, 2xCH(CH3)2), 4.27-4.14 (5H, m,  H-3’, H-4’, H-5’), 4.01-3.91 (2H, m, 
2xCHCH3), 1.36-1.26 (6H, m, 2xCHCH3), 1.21-1.11 (12H, m, 2xCOOCH(CH3)2). 13C-
NMR (MeOD, 125 MHz): d 20.49, 20.56, 20.61, 20.64, 20.69 (CHCH3), 21.90, 22.00, 
22.02 (CH(CH3)2), 51.87 (CHCH3), 66.51, 66.55, 66.66, 66.70 (C-4’, C-5’), 70.23, 70.30, 
70.32 (COOCH(CH3)2), 72.91 (C-1’), 76.94 (C-3’), 116.13, 116.42, 122.67, 122.70, 
122.79, 126.03, 126.55, 127.54, 127.80, 127.86, 128.87 (C-5, C-2 Naph, C-3 Naph, C-4 
Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph), 136.26 (C-4a Naph), 
138.42 (C-8), 147.92, 147.98, 150.02 (‘ipso’ Naph, C-4), 155.64 (C-2), 159.44 (C-6), 
174.72 (COOCH2Ph). EI MS= 916.3 (M+Na). Anal. Calcd for C41H49N7O12P2: C, 55.09; H, 
5.53; N, 10.97. Found: C, 54.62; H, 5.56; N, 10.60. 
 
Synthesis of 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}- 
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6,9-dihydro-1H-purin-6-one-[1-naphthyl(isopropoxy-L-alaninyl)]phosphate (16). A 
solution of 8 (0.070 g, 0.11 mmol) in 2-propanol (4 mL) was stirred under reflux for 24 h. 
After this period the solvent was removed and the residue purified by preparative reverse 
phase HPLC (gradient elution of H2O/CH3CN= from 100/0 to 0/100 in 35 min) to give 16 
as a colourless solid (33%, 0.021 g). 31P-NMR (MeOD, 202 MHz): d 4.40, 4.36, 4.34, 
4.27. 1H-NMR (MeOD, 500 MHz): d 8.20-8.06 (1H, m, Naph), 7.90-7.85 (1H, m, Naph), 
7.83-7.79 (1H, m, H-8), 7.75-7.66 (1H, m, Naph), 7.59-7.49 (2H, m, Naph), 7.49-7.36 
(2H, m, Naph), 5.51-5.45 (2H, m, H-1’), 5.03-4.94 (1H, m, CH(CH3)2), 4.39-4.11 (2H, m,  
H-5’), 4.05-3.91 (2H, m, H-3’, CHCH3,), 3.65-3.47 (2H, m, H-4’), 1.40-1.29 (3H, m, 
CHCH3), 1.26-1.14 (6H, m, COOCH(CH3)2). 13C-NMR (MeOD, 125 MHz): d 20.46 (d, JC–P 
= 6.7 Hz, CHCH3), 20.57 (d, JC–P = 6.7 Hz, CHCH3), 20.68 (d, JC–P = 6.6 Hz, CHCH3), 21.90 
(d, JC–P = 2.3 Hz, CH(CH3)2), 21.99 (d, JC–P = 2.9 Hz, CH(CH3)2), 51.83 (CHCH3), 61.78, 
61.92 (2s, C-4’), 67.36 (d, JC–P = 5.4 Hz, C-5’), 67.45 (d, JC–P = 5.7 Hz, C-5’), 70.17 
(COOCH(CH3)2), 70.26 (d, JC–P = 5.6 Hz, COOCH(CH3)2), 72.89, 73.06, (C-1’), 78.95 (d, JC–
P = 7.3 Hz, C-3’), 79.21 (d, JC–P = 7.6 Hz, C-3’), 116.31, 116.34, 116.37, 116.40, 117.48, 
117.56, 122.70, 122.74, 122.83, 125.98, 126.55, 127.50, 127.78, 127.80, 127.88, 127.93, 
128.85 (C-5, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, 
C-8a Naph), 136.27 (C-4a Naph), 139.70, 139.75 (C-8), 147.97, 148.05 (‘ipso’ Naph, C-
4), 155.72 (C-2), 159.46 (C-6), 174.52 (COOCH2Ph). EI MS= 597.1832 (M+Na). Anal. 
Calcd for C25H31N6O8P×H2O: C, 50.68; H, 5.61; N, 14.18. Found: C, 50.75; H, 5.44; N, 
13.89. 
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Synthesis of 
9-[({1-hydroxy-3-[(4-methoxyphenyl)diphenylmethoxy]propan-2-yl}oxy)methyl]-2-{[
(4-methoxyphenyl)diphenylmethyl]amino}-6,9-dihydro-1H- 
purin-6-one (23) and 
9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-2-{[(4-methoxyphenyl)diphenylmethyl]a
mino}-6,9-dihydro-1H-purin-6-one (24). A solution of 1 (0.50 g, 1.96 mmol), 
monomethoxytrityl chloride (1.33 g, 4.32 mmol), triethylamine (0.82 mL, 5.88 mmol) 
and 4-(dimethylamino)pyridine (5 mg) in DMF (5 mL) was stirred at room temperature 
for 2 h. The reaction was then quenched with methanol and the solvent was removed. The 
residue was taken up in ethyl acetate and the solution washed with aqueous NaHCO3 and 
water. The solution was dried over MgSO4, filtered and concentrated. The residue was 
purified by column chromatography gradient elution of DCM/MeOH (98/2, then 96/4, 
then 94/6) to give 23 as a colourless solid (53%, 0.84 g). 1H-NMR (MeOH, 500 MHz): d 
7.79 (1H, s, H-8), 7.32-6.73 (28H, m, Ph), 5.06 (2H, s, H-1’), 3.82 (3H, s, CH3O), 3.66 
(3H, s, CH3O), 3.57-3.54 (1H, m, H-4’), 3.28-3.18 (2H, m, CH2OH), 2.87-2.79 (2H, m, 
CH2OMMT). Compound 24 was obtained as a colourless solid (30% 0.30 g).  1H-NMR 
(MeOH, 500 MHz): d 7.74 (1H, s, H-8), 7.38-6.87 (14H, m, Ph), 3.80 (3H, s, CH3O), 
3.66-3.60 (1H, m, CH2CHCH2), 3.49-3.43 (4H, m, CH2CHCH2). 
 
Synthesis of 
9-[({1-hydroxy-3-[(4-methoxyphenyl)diphenylmethoxy]propan-2-yl}oxy)methyl]-2-{[
(4-methoxyphenyl)diphenylmethyl]amino}-6,9-dihydro-1H- 
purin-6-one-[1-phenyl-(benzoxy-L-alaninyl)] phosphate (25). Prepared according to 
standard procedure A, from 23 (0.45 g, 0.58 mmol) in anhydrous THF (10 mL), tBuMgCl 
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(1.0 M THF solution, 1.12 mL, 1.12 mmol), phenyl-(benzoxy-L-alaninyl)-
phosphorochloridate (0.45 g, 1.27 mmol) in anhydrous THF (2 mL) and the reaction 
mixture was stirred at room temperature overnight. The solvent was removed under 
reduced pressure and the residue was purified by column chromatography, gradient 
elution of DCM/MeOH = 100/0 then 98/2 to give 25 as a colourless solid (38%, 0.25 g). 
31P-NMR (MeOD, 202 MHz): d 3.32, 3.30, 3.27, 3.16. 1H-NMR (MeOD, 500 MHz): d 
7.74-7.73 (1H, 2s, H-8), 7.34-6.70 (38H, m, PhO, OCH2Ph, NH-C(Ph)3, O- C(Ph)3), 5.17-
4.99 (2H, m, OCH2Ph), 4.95-4.89 (2H, m, H-1’), 3.79-3.60 (8H, m, CHCH3, H-3’, 2X 
PhOCH3) 3.17-3.07 (2H, m, CH2OP), 2.81-2.78 (2H, m, CH2OC(Ph)3), 1.85, 1.72 (3H, m, 
CHCH3).  
 
Synthesis of 
9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-2-{[(4-methoxyphenyl)diphenylmethyl]a
mino}-6,9-dihydro-1H-purin-6-one-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate 
(26). Prepared according to standard procedure A, from 24 (0.24 g, 0.46 mmol) in 
anhydrous THF (8 mL) tBuMgCl (1.0 M THF solution, 0.92 mL, 0.92 mmol), 1-naphthyl-
(benzoxy-L-alaninyl)-phosphorochloridate (0.37 g, 0.92 mmol) in anhydrous THF (2 mL) 
and the reaction mixture was stirred at room temperature overnight. The solvent was 
removed under reduced pressure and the residue was purified by column 
chromatography, gradient elution of DCM/MeOH = 100/0, 98/2, then 96/2 to give 26 as a 
colourless solid (35%, 0.15 g). 31P-NMR (MeOD, 202 MHz): d 3.91, 3.93, 3.96. 1H-NMR 
(MeOD, 500 MHz): d 8.19-8.15 (m, 0.5H, H-8 Naph), 8.11-8.08 (m, 0.5H, H-8 Naph), 
7.91-7.89 (m, 1H, H-6 Naph), 7.69,-7.68 (m, 1H, H-8), 7.66-6.75 (m, 24H, PhO, 
OCH2Ph, NH-C(Ph)3), 5.1, 5.08, 5.04, 5.03 (4s, 2H, OCH2Ph), 4.95-4.91 (2H, m, H-1’), 
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4.04-3.72 (8H, m, CHCH3, CH2OH), 3.67 (3H, s, PhOCH3), 3.52-3.44 (1H, m, H-3’), 
3.29-3.08 (2H, m, CH2OP), 1.34-1.30 (3H, m, CHCH3). 
 
Synthesis of 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}- 
6,9-dihydro-1H-purin-6-one-[1-phenyl-(benzoxy-L-alaninyl)] phosphate (27). para-
toluene sulfonic acid (0.09 g, 0.48 mmol) was added to a solution of 25 (0.11 g, 0.1 
mmol) in DCM (3.5 mL) and MeOH (1.5 mL). The mixture was stirred at room 
temperature for 4 h. After this period the solvent was removed under reduced pressure 
and the residue was purified by preparative TLC chromatography, gradient elution of 
DCM/MeOH (98/2 then 96/4 then 94/6) to give a solid which was further purified by 
preparative reverse phase HPLC (gradient elution of H2O/MeOH 90/10 to 80/20 in 5 min, 
80/20 isocratic 15 min, then to 0/100 in 5 min) to give 27 as a colourless solid (28%, 0.02 
g). 31P-NMR (MeOD, 202 MHz): d 3.92, 3.83, 3.63, 3.61. 1H-NMR (MeOD, 500 MHz): d 
7.84, 7.83 (0.5H, 2s, H-8), 7.80, 7.79 (0.5H, 2s, H-8) 7.40-7.30 (7H, m, PhO, OCH2Ph), 
7.21-7.13 (3H, m, PhO, OCH2Ph), 5.54, 5.53, 5.51, 5.50 (2H, 4s, H-1’), 5.17, 5.16, 5.15, 
5.14 (2H, 4s, OCH2Ph), 4.23-3.91 (4H, m, H-5’, H-3’, CHCH3), 3.61-3.47 (2H, m, H-4’), 
1.38-1.31 (3H, m, CH3). 13C-NMR (MeOD, 126 MHz): d 20.50 (d, JC–P = 6.4 Hz, CHCH3), 
20.40 (d, JC–P = 6.4 Hz, CHCH3), 20.37 (d, JC–P = 7.1 Hz, CHCH3), 51.62, 51.75 (NHCH), 
61.91, 61.99, 62.02 (3s, CH2CHCH2), 67.31 (d, JC–P = 5.9 Hz, CH2CHCH2), 67.25 (d, JC–P = 
2.8 Hz, CH2CHCH2), 67.20 (d, JC–P = 5.7 Hz, CH2CHCH2), 67.97, 68.00, 68.03 (3s, 
OCH2Ph), 73.07, 73.11, 79.13 (3s, C-1’) 79.24 (d, JC–P = 7.6 Hz, CH2CHCH2), 79.25 (d, JC–P 
= 5.6 Hz, CH2CHCH2), 79.30 (d, JC–P = 7.4 Hz, CH2CHCH2), 117.55, 121.41, 121.44, 
121.47, 121.49, 121.51, 121.53, 121.54, 126.09, 126.12, 126.15,129.27, 129.32, 129.33, 
129.35, 129.58, 129.61, 129.63, 130.76 (C-5, PhO, OCH2Ph), 137.30 (‘ipso’ OCH2Ph), 
 52 
139.8 (s, C-8), 152.12, 152.17, 152.19, 152.23 (4s, C-4), 153.30 (‘ipso’OPh), 155.68 (C-
2), 159.37 (C-6), 174.92 (d, JC–P = 4.4 Hz, COOCH2Ph), 174.82 (d, JC–P = 5.4 Hz, 
COOCH2Ph), 174.72 (d, JC–P = 4.6 Hz, COOCH2Ph). EI MS= 595.162 (M+Na). HPLC = 
H2O/ACN from 100/0 to 0/100 in 15 min, then 0/100 isocratic 5 min = retention time 9.29 
min; H2O/MeOH from 100/0 to 0/100 in 15 min, then 0/100 isocratic 5 min = retention 
time 13.18 min. 
 
Synthesis of 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}- 
6,9-dihydro-1H-purin-6-one-[1-naphthyl-(benzoxy-L-alaninyl)] phosphate (28). 
para-toluene sulfonic acid (0.09 g, 0.48 mmol) was added to a solution of 26 (0.09 g, 0.1 
mmol) in DCM (3.5 mL) and MeOH (1.5 mL). The mixture was stirred at room 
temperature for 4 h. After this period the solvent was removed under reduced pressure 
and the residue was purified by preparative TLC, gradient of DCM/MeOH (98/2 then 
96/4 then 94/6) to give 28 as a colourless solid (25%, 0.015 g). 31P-NMR (MeOD, 202 
MHz): d 4.29, 4.24, 4.18, 4.09. 1H-NMR (MeOD, 500 MHz): d 8.16-8.09 (m, 1H, H-8 
Naph), 7.90, 7.80 (1H, 2s, H-6 Naph), 7.79-7.75 (1H, m, H-8), 7.72-7.70 (1H, m, H-2 
Naph), 7.54-7.24 (12H, m, PhO, OCH2Ph), 5.46-5.42 (2H, m, H-1’), 5.13, 5.12, 5.08, 
5.07 (2H, 4s, OCH2Ph), 4.29-4.06 (4H, m, OCH2CHCH2O, CHCH3), 3.97-3.90 (2H, m, 
OCH2CHCH2O), 1.38-1.31 (3H, m, CHCH3). 13C-NMR (MeOD, 126 MHz): d 20.38 (d, JC-P 
= 7.3 Hz, CHCH3), 20.43 (d, JC-P = 6.7 Hz, CHCH3), 20.53 (d, JC-P = 6.5 Hz, CHCH3), 51.80, 
51.85 (CHCH3), 61.84, 61.94, 61.97 (3s, CH2CHCH2), 67.43 (d, J = 5.6 Hz, CH2CHCH2), 
67.49 (d, J = 3.3 Hz, CH2CHCH2), 67.53 (d, J = 3.3 Hz, CH2CHCH2), 67.97, 68.01, 68.04 
(3s, OCH2Ph), 72.96, 73.00, 73.08, 79.10 (4s, C-1’), 79.11 (d, JC–P = 7.8 Hz, CH2CHCH2), 
79.25 (d, JC–P = 6.0 Hz, CH2CHCH2), 79.31 (d, JC–P = 6.4 Hz, CH2CHCH2), 116.34, 116.36, 
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116.39, 116.42, 116.45, 116.47, 122.70, 122.74, 122.47, 125.99, 126.01, 126.55, 127.50, 
127.53, 127.79, 128.87, 129.22, 129.27, 129.30, 129.32, 129.34, 129.54, 129.58, 129.60 
(C-5, PhO, OCH2Ph), 136.30, 137.23 (‘ipso’ OCH2Ph, C4aNaph), 139.73 (C-8), 147.98, 
148.03 (2s, C-4), 153.27 (‘ipso’OPh), 155.65 (C-2), 159.34 (C-6), 174.74 (d, JC–P = 4.7 Hz, 
COOCH2Ph), 174.86 (d, JC–P = 5.3 Hz, COOCH2Ph), 174.96 (d, JC–P = 4.5 Hz, COOCH2Ph). 
EI MS= 645.187 (M+Na). HPLC = H2O/ACN from 100/0 to 0/100 in 15 min, then 0/100 
isocratic 5 min = retention time 10.49 min; H2O/MeOH from 100/0 to 0/100 in 15 min, 
then 0/100 isocratic 5 min = retention time 13.93 min. 
 
Synthesis of 
N'-{9-[4-hydroxy-3-(hydroxymethyl)butyl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-N,N-di
methylmethanimidamide-[ethoxy-L-alaninyl)] cyclic phosphate (73). To a stirring 
solution of 6 (0.30 g, 0.97 mmol) in anhydrous THF (10 mL) and anhydrous pyridine (5 
mL) was added tBuMgCl (1.0 M THF solution, 2.00 mL, 2.00 mmol) and the reaction 
mixture was stirred at room temperature for 30 min. After this period, a solution of 
(ethoxy-L-alaninyl)-dichlorophosphate (0.45 g, 1.93 mmol) in anhydrous THF (5 mL) 
was added and the reaction mixture was stirred at room temperature for 24 h. After this 
period, anhydrous pyridine (5 mL) and tBuMgCl (1.0 M THF solution, 2.00 mL, 2.00 
mmol) were added and the reaction mixture was stirred at room temperature for 16 h. 
After this period the solvent was removed and the residue purified by column 
chromatography gradient elution of DCM, then DCM/MeOH = 98/2, 92/8 then 80/20, to 
give 73 as a colourless gum (93%, 0.43 g). 31P-NMR (MeOD, 202 MHz): d 3.53, 2.44. 
 
Synthesis of 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9- 
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dihydro-1H-purin-6-one-[ethoxy-L-alaninyl)] cyclic phosphate (74). A solution of 73 
(0.43 g, 0.91 mmol) in 2-propanol (20 mL) was stirred at reflux for 9 h. After this period 
the solvent was removed and the residue purified by column chromatography gradient 
elution of DCM/MeOH = 97/3, 94/6, 90/10 then 85/15 to give a colourless solid, which 
was further purified by preparative TLC (gradient elution of DCM/MeOH = 97/3 then 
95/5) to give 74 as a colourless solid (11%, 0.040 g). 31P-NMR (MeOD, 202 MHz): d 
3.73, 2.89. 1H-NMR (MeOD, 500 MHz): d 7.91 (1H, s, H-8), 5.70-5.55 (2H, m, H-1’), 
4.63-4.30 (5H, m, H-3’, H-4’, H-5’), 4.26-4.10 (2H, m, CH2CH3), 3.93-3.76 (1H, m, 
CHCH3), 1.45-1.32 (3H, m, CH2CH3), 1.31-1.24 (3H, m, CHCH3). 13C-NMR (MeOD, 125 
MHz): d 14.46, 14.49 (CH2CH3), 20.43 (d, JC–P = 6.4 Hz, CHCH3), 20.51 (d, JC–P = 6.6 Hz, 
CHCH3), 50.93, 51.34 (CHCH3), 62.29, 62.38 (CH2CH3), 69.89, 69.92, 69.94, 69.97, 
70.26, 70.31, 70.42, 70.46, 70.51, 70.85, 70.90 (C-3’, C-4’, C-5’), 71.26, 71.42 (C-1’), 
117.49 (C-5), 139.69 (C-8) 155.82 (C-2), 159.40 (C-6), 175.02 (d, JC–P = 5.8 Hz, 
COOCH2CH3), 175.11 (d, JC–P = 5.5 Hz, COOCH2CH3). EI MS= 417.12 (M+H) and 439.11 
(M+Na). HPLC = H2O/AcCN 95/5 to 0/100 in 30 min = retention time 7.75 min. 
 
Synthesis of 2-((2-amino-6-chloro-9H-purin-9-yl)methoxy)-3-hydroxypropyl acetate 
(76). A suspension of 6-chloro-diacetylated-penciclovir (1.17 g, 3.29 mmol) and 
anhydrous methanol (20 mL) was bubbled with ammonia gas (generated in situ by 
heating 35% ammonia solution at 50 °C) at 0 °C for 5.5 h. The solvent was then removed 
and the residue purified by column chromatography eluting with DCM/MeOH 95/5 to 
give 76 as a colourless solid (34%, 0.36 g). 1H-NMR (DMSO, 500MHz): d 8.15 (1H, s, 
H-8), 6.87 (2H, s, NH2), 4.15-4.12 (2H, t, J = 6.2 Hz, H-1’), 4.05-4.02 (2H, m, H-4’), 
3.99-3.95 (2H, m, H-5’), 1.99 (3H, s, CH3), 1.90-1.76 (2H, m, H-2’), 1.71-1.66 (1H, m, 
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H-3’). EI MS: 316.9 (M+H). HPLC = H2O/AcCN from 95/5 to 0/100 in 30 min = 
retention time 8.64 min. 
 
Synthesis of 2 2-[2-(2-amino-6-chloro-9H-purin-9-yl)ethyl]-3-hydroxypropyl acetate-
[1-phenyl(benzoxy-L-alaninyl)] phosphate (77). Prepared according to Standard 
Procedure A, from 76 (0.070 g, 0.23 mmol) in anhydrous THF (5 mL), tBuMgCl (1.0 M 
THF solution, 0.45 mL, 0.45 mmol) phenyl-(benzoxy-L-alaninyl)-phosphorochloridate 
(0.16 g, 0.45 mmol) in anhydrous THF (2 mL) and the reaction mixture was stirred at 
room temperature for 16 h. After this period, the solvent was removed and the residue 
purified by column chromatography gradient elution of DCM then DCM/MeOH 98/2, 
97/3 to give 77 as a colourless solid (28%, 0.04 g). 31P-NMR (MeOD, 202MHz): d 3.97, 
3.90, 3.38. 1H-NMR (MeOD, 500MHz): d 8.06 (0.5H, d, J = 8.1 Hz, H-8 of one 
diasteroisomer), 8.04 (0.5H, d, J = 4.9 Hz, H-8 of one diasteroisomer), 7.39-7.26 (7H, m, 
Ph, CH2Ph), 7.23-7.13 (3H, m, Ph, CH2Ph), 5.14, 5.13 (2H, 2s, CH2-Ph), 4.23-3.96 (7H, 
m, H-1’, H-4’, H-5’, CHCH3), 2.02, 2.02 (3H, 2s, COCH3), 2.00-1.81 (3H, m, H-2’, H-3’), 
1.38 (1.5H, d, J = 7.3 Hz, CHCH3 of one diasteroisomer), 1.36 (1.5H, d, J = 8.1 Hz, 
CHCH3 of one diasteroisomer); 13C-NMR (MeOD, 126MHz): d  20.36 (d, JC–P = 6.4 Hz, 
CHCH3), 20.73 (COCH3), 29.04, 29.11 (C-2’), 37.38 (d, JC–P = 7.5 Hz, C-3’), 37.45 (d, JC–P = 
8.0 Hz, C-3’), 42.33, 42.37, 42.42 (C-1’), 51.65, 51.82 (CHCH3), 64.57 (C-4’), 64.62 (d, 
JC–P = 3.0 Hz, C-4’),  67.36, 67.39, 67.41, 67.43, 67.47 (C-5’),  67.95, 67.94 (CH2Ph), 
121.39, 121.41, 121.43, 121.45, 121.48, 121.53, 121.56 (Ph, CH2Ph), 126.14 (C-5), 
129.23, 129.30, 129.56, 130.77 (Ph, CH2Ph), 137.26 (Ph), 144.47 (C-8), 151.57 (C-2), 
155.30 (C-4), 161.58 (C-6), 172.68 (COCH3), 174.72, 174.99 (COOCH2Ph); EI MS: 
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631.1 (M+H) 653.0 (M+Na); HPLC = H2O/AcCN from 95/5 to 0/100 in 30 min = 
retention time 18.56, 18.89 min. 
 
Antiviral Activity Assay 
HIV-1 inhibition by compounds was assessed in MT-4 cell cultures and in human tissue 
ex vivo. 
 
MT-4 cell cultures: One million of MT-4 cells suspended in 100 uL of fresh culture 
medium were incubated with 100 μL (7 ng of p24) of HIV-1 X4LAI.04 viral stock for 2h 
at 37 C. After incubation, cells were washed with 20 mL of PBS and resuspended in 10 
mL of fresh medium. 1 mL of infected cell suspensions were then transferred to 
microplate wells and tested compounds were added at appropriate concentrations. Cell 
cultures were then further incubated for 3 days at 37 ºC. After 3 days, p24 production was 
measured in the MT-4 cell culture supernatants. 
 
Human tissue culture ex vivo: Human tonsillar tissues were obtained from patients 
undergoing routine tonsillectomy at the Children’s National Medical Center (Washington 
DC) under an IRB-approved protocol. Tissues were dissected into 2- to 3-mm3 blocks and 
placed onto collagen sponge gels in culture medium at the air–liquid interface as 
described earlier.23 Human tonsillar tissues (27 blocks of tissue from each of n donors for 
each experimental condition) were pretreated with compounds overnight and then 
infected with HIV-1 X4LAI.04 (Rush University Virology Quality Assurance 
Laboratory, Chicago, IL). The tissue culture was kept for 12 days, and drugs were 
replenished after each medium change (every 3 days). 
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Evaluation of antiviral activity of compounds: We measured p24gag using a bead-based 
Luminex assay as described earlier.25 We then evaluated the antiviral activity of each 
compound by measuring inhibition of human HIV-1 replication in MT-4 cell cultures and 
in human lymphoid tissues. For each compound, in MT-4 cell cultures or in lymphoid 
tissue ex vivo, HIV-1 inhibition at each single drug concentration was defined by the 
following formula: inhibition = (1-Rcompounds/RCtl)x100, where Rcompounds and 
RCtl are the amounts of p24 accumulated in the medium in compound-treated cultures 
and in untreated cultures, respectively. The results are given as the concentration required 
to suppress viral replication by 50% ([EC50]). 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 
(HSV-1) strain KOS, thymidine kinase-deficient (TK-) HSV-1 KOS strain resistant to 
ACV (ACVr), herpes simplex virus type 2 (HSV-2) strains Lyons and G, varicella-zoster 
virus (VZV) strain Oka, TK- VZV strain 07-1, human cytomegalovirus (HCMV) strains 
AD-169 and Davis, and human immunodeficiency virus type 1 strain IIIB. The antiviral, 
other than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or 
plaque formation in human embryonic lung (HEL) fibroblasts. Confluent cell cultures in 
microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the 
virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) 
(VZV) in the presence of varying concentrations of the test compounds. Viral 
cytopathicity or plaque formation was recorded as soon as it reached completion in the 
control virus-infected cell cultures that were not treated with the test compounds. 
Antiviral activity was expressed as the EC50 (50% effective concentration) or compound 
concentration required to reduce virus-induced cytopathogenicity or viral plaque 
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formation by 50%. The MCC (minimal cytotoxic concentration) values were determined 
as the compound concentration required to afford a microscopically visible alteration of 
HEL cell morphology. 
 
Cytostatic Activity Assays  
All assays were performed in 96-well microtiter plates. To each well were added (5−7.5) 
× 104 CEM cells and a given amount of the test compound. The cells were allowed to 
proliferate for 72 h at 37 °C in a humidified CO2-controlled atmosphere. At the end of the 
incubation period, the cells were counted in a Coulter counter. The IC50 (50% inhibitory 
concentration) was defined as the concentration of the compound that inhibited cell 
proliferation by 50%. 
Viability assays in MT-4 cell cultures. Viability assays were performed in MT-4 cell 
cultures with the Nucleocounter automated cell counting system (ChemoMetec). Total 
number of cells and number of dead cells in the cultures untreated and treated with ACV 
ProTides were enumerated using a propidium iodide-based assay according to the 
manufacturers’ protocol. Data were collected and analyzed using Nucleoview software 
(Chemometec, Denmark). We defined CC50 as the compound concentration that reduced 
the viability of the MT-4 by 50% and IC50 as the compound concentration that inhibited 
MT-4 or CEM cell growth by 50%. 
 
Molecular Modelling 
All molecular modelling studies were performed on a MAC pro 2.66 GHz Quad-Core 
Intel Xeon, running Ubuntu. A database of 3600 compounds were built using Molecular 
Operating Environment (MOE)26 and minimized using the MMFF94x force field before 
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docking. HIV-RT (PDB code: 1T05), human adenylate kinase (PDB: 2C95), mouse 
guanylate kinase (PDB: 1LVG) were downloaded from the RCSB Protein Data Bank and 
pre-processed using MOE. Hydrogen atoms were added to the crystal structures and 
minimised with MOE until a gradient of 0.05 Kcal mol-1 Å-1 was reached using MMFF94x 
force field. The partial charges were automatically calculated. An homology model of the 
human polymerase γ was used.18 Docking simulations were performed using PLANTS27 
and docking results were analyzed with MOE. 
 
Associated Content 
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